Outstanding Year for Biotechnology -Average Performance is up 35% YTD Many Rayno Life Science Stocks have outperformed the sector and the ETFs: Albany Molecular Inc. (AMRI), a contract research organization with long term experience in drug discovery, development and manufacturing soared 82% YTD on improved financial results.The stock is a turnaround story and is still […]
End of Year Rally Crushed By Turmoil in Budget Talks Up until late yesterday investors were optimistic about a budget deal with the “Kubuki Theater” Congress. You have heard enough about the fiscal cliff and non-starter proposals to avert the fiscal cliff so let this link suffice. Up until now the market expected some deal […]
Rayno Tools and Diagnostics Stocks Continue Rally Tools and Diagnostic stocks have been the laggards in the Rayno Life Sciences Portfolio compared to biopharmaceutical stocks. Selected stocks within the Rayno Portfolio have perked up and we suggest some rebalancing. Our new long term buy Cepheid (CPHD) is showing accumulation. Underperforming stocks such as Alere (ALR) […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.